HHS Public Access

Author manuscript

Org Lett. Author manuscript; available in PMC 2020 January 02.

Published in final edited form as:

Org Lett. 2008 November 20; 10(22): 5155–5158. doi:10.1021/ol8020989.

Cell-Permeable Esters of Diazeniumdiolate-Based Nitric Oxide Prodrugs

Harinath Chakrapani[*,†], **Anna E. Maciag**[‡], **Michael L. Citro**[‡], **Larry K. Keefer**[†], **Joseph E. Saavedra**[*,‡]

[†]Chemistry Section, Laboratory of Comparative Carcinogenesis, National Cancer Institute at Frederick, Frederick, Maryland 21702, USA

[‡]Basic Research Program, SAIC-Frederick, National Cancer Institute at Frederick, Frederick, Maryland 21702, USA

Abstract



Although O^2-(2,4-dinitrophenyl) derivatives of diazeniumdiolate-based nitric oxide (NO) prodrugs bearing a free carboxylic acid group were activated by glutathione to release NO, these compounds were poor sources of intracellular NO and showed diminished anti-proliferative activity against human leukemia HL-60 cells. The carboxylic acid esters of these prodrugs, however, were found to be superior sources of intracellular NO and potent inhibitors of HL-60 cell proliferation.

Nitric oxide (NO) donors of the diazeniumdiolate class are routinely used as sources of nitric oxide for chemical and biological applications.1 For example, the 1-[2-(carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolate (PROLI/NO) anion dissociates in pH 7.4 phosphate buffer to form nitric oxide with a half-life of 2 s (Scheme 1).2

Under aerobic conditions, one of the possible byproducts of PROLI/NO decomposition is *N*-nitrosoproline (NPRO, Scheme 2).2e

In contrast to most other *N*-nitrosamines,3 which are potent carcinogens, NPRO showed no carcinogenic activity at a range of dosages in numerous animal models.2e,4 For example, *N*-nitrosodiethylamine was shown to induce tumors in a rat model in different organs and sites (Table 1, entry 2).3b

chakrah@ncifcrf.gov; saavj@ncifcrf.gov.

However, even at 100-fold higher doses than those of *N*-nitrosodiethylamine, NPRO showed no evidence of tumor formation (Table 1, entry 1).3b Not just NPRO, but other *N*-nitrosamines with a carboxylic acid group were reported to show no carcinogenic activity in a rodent model (Table 1, entries 5, 6).3b Thus, the use of diazeniumdiolate anions with a carboxylic acid functionality (such as PROLI/NO) would be preferable in clinical settings due to the formation of relatively innocuous byproducts.

O^2-Derivatization of diazeniumdiolate anions using a suitable protective group facilitates site-directed delivery of nitric oxide.5 For example, *O*^{2}-(2,4-dinitrophenyl) diazeniumdiolates are reported to be activated by glutathione (GSH) to form NO (Scheme 3).6 Glutathione is an essential component of the biochemical machinery and its intracellular distribution ranges from 0.1-10 mM.7

Earlier, we prepared the O^2-(2,4-dinitrophenyl) derivative of PROLI/NO, **2**, from diazeniumdiolate salt **1** in two steps (Scheme 4).8

Using a similar procedure, carboxylic acids **3**9 and **4** were prepared (Figure 1).

A chemiluminescence assay was used to study glutathione-activated nitric oxide formation in aqueous buffer (Table 2). Next, the intracellular NO release by these compounds was determined using the nitric oxidesensitive fluorophore, 4-amino-5-methylamino-2′,7′-difluorofluorescein diacetate (DAF-FM diacetate);10 briefly, human leukemia HL-60 cells were pre-loaded with DAF-FM diacetate, followed by treatment with DMSO solutions of **2**, **3**, and **4**; fluorescence measurements after 40 min provided estimates of levels of intracellular NO (Table 2).

While they were excellent sources of nitric oxide in the presence of glutathione in aqueous phosphate buffer, the carboxylic acids **2**, **3**9 and **4** did not form significantly higher levels of intracellular NO than the DMSO control (Table 2). These intracellular NO release observations are consistent with their diminished ability to inhibit in vitro proliferation of human leukemia HL-60 cells (Table 2).9,11

In order to improve cell permeability, it was envisaged that a free carboxylic acid group be masked as an ester; as a neutral, non-ionizable species, an ester should be able to cross the cell membrane.12 Subsequent intracellular ester hydrolysis and glutathione activation should generate the spontaneously nitric oxide-forming diazeniumdiolate anion, which upon decomposition would generate a secondary amine linked to a carboxylic acid such as L-proline (Figure 2).

Accordingly, **5**, the methyl ester of **2**, was prepared by treating the carboxylic acid with diazomethane (Scheme 3). Using a similar procedure, compounds **6** and **7** were prepared from **3** and **4**, respectively (Figure 3). Next, diazeniumdiolation of the requisite secondary amines, followed by arylation, produced esters of isonipecotic acid, **8** and **9**, and nipecotic acid, **10** (Figure 3).

Glutathione-activated nitric oxide release for these esters was determined. Quantitative nitric oxide yields from a majority of the prodrug esters were observed (Table 2). Then, these

esters were tested for their ability to deliver nitric oxide intracellularly using the DAF-FM diacetate assay. All the esters were found to release much higher levels of intracellular NO than their carboxylic acid counterparts (Table 2). Under these conditions, the prodrug **6**, which released 4 moles of NO in the presence of GSH, produced the most intracellular nitric oxide. A plot of the relative levels of intracellular NO shows that esters **8**, **9** and **10** formed nearly 3-fold higher levels of NO than **2** (Figure 4).

Finally, the ability of these compounds to inhibit proliferation of human leukemia HL-60 cells was determined. Esterification of the carboxylic acids **2**-**4** significantly improved in vitro anti-proliferative activity of the resulting esters **5**-**7** against HL-60 human leukemia cells (Table 2). For example, the PROLI/NO ester analogues **5** and **6** were superior inhibitors of HL-60 cell proliferation relative to their carboxylic acid counterparts **2** and **3** (Table 2). All the other esters (**7**-**10**) showed excellent anti-proliferative activity that was consistent with elevated levels of intracellular nitric oxide. While other mechanisms might be operational, cell permeability of O^2-(2,4-dinitrophenyl) diazeniumdiolates to release nitric oxide intracellularly appears to be a crucial determinant of inhibitory potential.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research, as well as by National Cancer Institute contract N01-CO-12400 to SAIC-Frederick.

References

1. (a)Scatena R, Bottoni P, Martorana GE, Giardina B. Expert Opin Investig Drugs. 2005; 14:835–846. (b)Keefer LK. Curr Top Med Chem. 2005; 5:625–636. [PubMed: 16101424] (c)King SB. Free Rad Biol Med. 2004; 37:735–736. [PubMed: 15304248] (d)Keefer LK. Annu Rev Pharmacol Toxicol. 2003; 43:585–607. [PubMed: 12415121] (e)Hrabie JA, Keefer LK. Chem Rev. 2002; 102:1135–1154. [PubMed: 11942789] (f)Keefer LK, Nims RW, Davies KM, Wink DA. Methods Enzymol. 1996; 268:281–293. [PubMed: 8782594]
2. (a)Saavedra JE, Southan GJ, Davies KM, Lundell A, Markou C, Hanson SR, Adrie C, Hurford WE, Zapol WM, Keefer LK. J Med Chem. 1996; 39:4361–4365. [PubMed: 8893830] (b)Chen C, Hanson SR, Keefer LK, Saavedra JE, Davies KM, Hutsell TC, Hughes JD, Ku DN, Lumsden AB. J Surg Res. 1997; 67:26–32. [PubMed: 9070177] (c)Champion HC, Bivalacqua TJ, Wang R, Kadowitz PJ, Keefer LK, Saavedra JE, Hrabie JA, Doherty PC, Hellstrom WJG. J Urol. 1999; 161:2013–2019. [PubMed: 10332492] (d)Bivalacqua TJ, Champion HC, De Witt BJ, Saavedra JE, Hrabie JA, Keefer LK, Kadowitz PJ. J Cardiovasc Pharmacol. 2001; 38:120–129. [PubMed: 11444495] (e)Waterhouse DJ, Saavedra JE, Davies KM, Citro ML, Xu X, Powell DA, Grimes GJ, Potti GK, Keefer LK. J Pharm Sci. 2006; 95:108–115. [PubMed: 16315224]
3. (a) Lijinsky, W. Chemistry and Biology of N-Nitroso Compounds. Cambridge University Press; Cambridge: 1992. (b)Lijinsky W. Cancer Metastasis Rev. 1987; 6:301–356. [PubMed: 3319273] (c) Lijinsky, W. Chemical Carcinogenesis. Feo, F, Pani, P, Columbano, A, Garcea, R, editors. Plenum Publishing Corp.; New York: 1988. 639–647. (d) Lijinsky, W. Genotoxicology of N-Nitroso Compounds. Rao, TK, Lijinsky, W, Epler, JL, editors. Plenum Publishing Corp.; New York: 1984. 189–231. (e)Pool BL, Eisenbrand G, Preussmann R, Schlehofer JR, Schmezer P, Weber H, Wiessler M. Food Chem Toxic. 1986; 24:685–691.(f)Druckrey H, Preussmann R, Ivankovic R, Schmal D. Z Krebsforsch. 1967; 69:103–121. [PubMed: 4230610] (g)Lijinsky W, Reuber MD, Riggs CW. Cancer Res. 1981; 41:4997–5003. [PubMed: 7307000]

4. (a)Brunnemann KD, Enzmann HG, Perrone CE, Iatropoulos MJ, Williams GM. Arch Toxicol. 2002; 76:606–612. [PubMed: 12373457] (b)Negishi T, Shiotani T, Fujikawa K, Hayatsu H. Mutat Res. 1991; 252:119–128. [PubMed: 1901957] (c)Mirvish SS, Bulay O, Runge RG, Patil K. J Natl Cancer Inst. 1980; 64:1435–1442. [PubMed: 6929379] (d)Nixon JE, Wales JH, Scanlan RA, Bills DD, Sinnhuber RO. Food Cosmetics Toxicol. 1976; 14:133–135.
5. (a)Wu X, Tang X, Xian M, Wang PG. Tetrahedron Lett. 2001; 42:3779–3782.(b)Showalter BM, Reynolds MM, Valdez CA, Saavedra JE, Davies KM, Klose JR, Chmurny GN, Citro ML, Barchi JJ Jr, Merz SI, Meyerhoff ME, Keefer LK. J Am Chem Soc. 2005; 127:14188–14189. [PubMed: 16218605] (c)Saavedra JE, Billiar TR, Williams DL, Kim YM, Watkins SC, Keefer LK. J Med Chem. 1997; 40:1947–1954. [PubMed: 9207935] (d)Saavedra JE, Shami PJ, Wang LY, Davies KM, Booth MN, Citro ML, Keefer LK. J Med Chem. 2000; 43:261–269. [PubMed: 10649981] (e)Valdez CA, Saavedra JE, Showalter BM, Davies KM, Wilde TC, Citro ML, Barchi JJ Jr, Deschamps JR, Parrish D, El-Gayar S, Schleicher U, Bogdan C, Keefer LK. J Med Chem. 2008; 51:3961–3970. [PubMed: 18533711]
6. (a)Shami PJ, Saavedra JE, Bonifant CL, Chu J, Udupi V, Malaviya S, Carr BI, Kar S, Wang M, Jia L, Ji X, Keefer LK. J Med Chem. 2006; 49:4356–4366. [PubMed: 16821795] (b)Chakrapani H, Wilde TC, Citro ML, Goodblatt MM, Keefer LK, Saavedra JE. Bioorg Med Chem. 2008; 16:2657–2664. [PubMed: 18060792]
7. Meister A. J Biol Chem. 1988; 263:17205–17208. [PubMed: 3053703]
8. Chakrapani H, Showalter BM, Kong L, Keefer LK, Saavedra JE. Org Lett. 2007; 9:3409–3412. [PubMed: 17658755]
9. Andrei D, Maciag AE, Chakrapani H, Citro ML, Keefer LK, Saavedra JE. 2008Journal of Medicinal Chemistry.
10. Wardman F. Free Rad Biol Med. 2007; 43:995–1022. [PubMed: 17761297]
11. Chakrapani H, Goodblatt MM, Udupi V, Malaviya S, Shami PJ, Keefer LK, Saavedra JE. Bioorg Med Chem Lett. 2008; 18:950–953. [PubMed: 18178089]
12. (a)Rautio J, Kumpulainen H, Heimbach T, Oliyai R, Oh D, Jarvinen T, Savolainen J. Nature Rev Drug Disc. 2008; 7:255–270.(b)Liderer BM, Borchardt RT. J Pharm Sci. 2006; 95:1177–1195. [PubMed: 16639719] (c)Potter PM, Wadkins RM. Curr Med Chem. 2006; 13:1045–1054. [PubMed: 16611083] (d)Beaumont K, Webster R, Gardner I, Dack I. Curr Drug Metabol. 2003; 4:461–485.



Figure 1.
Compounds **3** and **4**.



Figure 2.
Design of cell-permeable nitric oxide prodrugs.



Figure 3.
Compounds **6**, **7**, **8**, **9** and **10**.



Figure 4.

Relative levels of intracellular nitric oxide formation upon treatment of HL-60 cells with compounds **2**-**10** (5 μM DMSO solutions) and DMSO (control) as determined by DAF-FM diacetate fluorescence study.



Scheme 1.
Dissociation of PROLI/NO to form NO.



Scheme 2.

Proposed mechanism for the formation of NPRO from the decomposition of PROLI/NO under aerobic conditions.



Scheme 3.
Glutathione-activated nitric oxide prodrugs.



Scheme 4.
Synthesis of **2** from **1**.



5

Scheme 3.
Synthesis of **5** by methylation of **2**.

Table 1

N-Nitrosamine-induced carcinogenesis in a rat model[a]

entry	*N*-nitroso	% of treated animals with tumors (organ developing tumors)
1	proline (NPRO)[b]	0
2	diethylamine[c]	95 (esophagus), 65 (liver)
3	pyrrolidine[d]	100 (liver)
4	piperidine[d]	100 (nasal), 67 (esophagus), 27 (liver)
5	pipecolic acid[d]	0
6	isonipecotic acid[d]	0

[a] administrated through drinking water; reference 3b.

[b] Total dose was 100 mmol/animal.

[c] Total dose was 1.0 mmol/animal.

[d] Total dose was 3.9-4.6 mmol/animal.

Table 2

Nitric oxide release, fluorescence measurements, and in vitro anti-proliferative activity

compd	nitric oxide yield (%)[a]	fluorescence[c] ± S. D.[d] (a.u.)	relative fluorescence (%)	IC_{50} (μM)[e]
DMSO	0	7.7 ± 0.25	100	-
2	100	9.5 ± 0.13	124	>20[f]
3	87[b]	7.9 ± 0.09	103	9.6[g]
4	96	7.4 ± 0.18	96	>20
5	98	17.0 ± 0.49	221	5.4
6	100[b]	28.9 ± 1.26	375	2.7
7	100	17.0 ± 0.49	221	6.0
8	100	24.3 ± 0.85	315	3.4
9	100	26.7 ± 0.85	346	4.8
10	99	24.9 ± 0.70	324	1.4

[a] Nitric oxide yields from the decomposition of the compound (50-100 μL of a 0.1 mM DMSO solution) in the presence of GSH (3.6 mM) in 0.1 M phosphate buffer (3.5 mL) containing 50 μM diethylenetriamine pentaacetic acid (DTPA) at pH 7.4 and 37 °C as measured by chemiluminescence.

[b] Calculated based on 4 moles of NO per mole of compound.

[c] Mean intracellular NO release measured using the NO-sensitive DAF-FM diacetate dye in HL-60 cells measured in arbitrary units (a.u.).

[d] Standard deviations of fluorescence measurements (3 independent experiments).

[e] The 50% inhibitory concentrations are reported for activity against proliferation of HL-60 cells.

[f] Reference 11.

[g] Reference 9.